Threonine is an essential amino acid that is critical for the synthesis of mucin — the glycoprotein that forms the protective mucus layer of the gastrointestinal tract and that is the primary defence against the luminal pathogens, toxins, and digestive enzymes that would otherwise damage the intestinal epithelium. Threonine is the most abundant amino acid in mucin, constituting approximately 25-30% of the total amino acid content of intestinal mucin, and it is this threonine-rich mucin layer that is the frontline of the gut immune system. The mucus layer of the gastrointestinal tract is composed of two layers — an inner firmly adherent layer that is virtually impenetrable to bacteria and a looser outer layer that is colonised by the commensal gut microbiota. Both layers are composed primarily of mucin, and both depend on adequate threonine availability for their synthesis and maintenance. When threonine availability is inadequate, mucin synthesis is reduced, the mucus layer is thinner and more permeable, and the intestinal epithelium is more vulnerable to damage from pathogens, toxins, and inflammatory mediators.
Mucin Synthesis and the Mucus Barrier
Mucins are high-molecular-weight glycoproteins that are synthesised and secreted by the goblet cells of the intestinal epithelium. They are characterised by a protein core that is rich in threonine residues, which are O-glycosylated with short oligosaccharide chains (predominantly N-acetylgalactosamine, galactose, sialic acid, and fucose) that give mucin its gel-forming properties. The O-glycosylation of threonine residues in the mucin protein core is the critical step in mucin synthesis — it is this glycosylation that allows mucin to form the high-molecular-weight polymers that give the mucus layer its gel-like mechanical properties and its ability to act as a protective barrier. When threonine availability is inadequate, the O-glycosylation of mucin is reduced, the mucin polymers are smaller and less stable, and the mucus layer that is synthesised is less viscous, less adherent, and less able to protect the underlying intestinal epithelium from damage.
The clinical importance of the mucus barrier is most clearly seen in the conditions that are characterised by mucus barrier dysfunction — including inflammatory bowel disease (IBD, which includes Crohn disease and ulcerative colitis), where the mucus layer is thinner and more permeable than in healthy individuals; celiac disease, where the inflammatory response to gluten damages the intestinal epithelium and impairs mucin synthesis; and small intestinal bacterial overgrowth (SIBO), where the reduction in the mucus barrier allows bacteria to attach to the intestinal epithelium and to proliferate to the levels that produce symptoms. In all of these conditions, the adequacy of the mucus barrier is a critical determinant of disease severity and of the response to treatment.
Threonine and Gut Immunity
Beyond its structural role in mucin, threonine also has specific functions in the immune system — it is required for the synthesis of the immunoglobulins (antibodies) that are secreted by the plasma cells of the gut-associated lymphoid tissue (GALT), and it is required for the synthesis of the cytokines and chemokines that coordinate the immune response to intestinal pathogens. The gut immune system is one of the most complex and important immune organs in the body — it must simultaneously tolerate the commensal gut microbiota and the dietary antigens that are present in the intestinal lumen while mount an effective immune response to pathogenic bacteria, viruses, and parasites. This tolerance-responsiveness balance is orchestrated by the gut immune system, and threonine plays a critical role in maintaining this balance by supporting the synthesis of the immunoglobulins (particularly IgA, which is the primary immunoglobulin of the gut lumen) and the cytokines that regulate the immune response.
Practical Application
For general gut barrier support, the evidence-based approach is to ensure adequate threonine intake from dietary protein (threonine is abundant in meat, fish, poultry, eggs, and dairy) and to supplement with threonine at 1-3g daily in divided doses when gut barrier dysfunction is suspected or confirmed. The evidence for threonine supplementation in gut barrier dysfunction is moderately strong — studies in animal models of intestinal inflammation show that threonine supplementation improves mucin synthesis, restores the mucus barrier, and reduces intestinal inflammation, and human studies in people with IBD and in people with gut barrier dysfunction suggest that threonine supplementation may be beneficial in these conditions. For comprehensive gut barrier support, threonine pairs well with glutamine (which is the primary fuel for the intestinal epithelium and which supports gut barrier function through its effects on epithelial cell proliferation and tight junction integrity), with the omega-3 fatty acids (which have anti-inflammatory effects in the gut), with zinc (which is required for the synthesis of the tight junction proteins that regulate intestinal permeability), and with the probiotics (which compete with pathogens for colonisation of the mucus layer and which support the gut immune system through their effects on IgA secretion and on the regulation of the inflammatory response).
Leave a Reply